Prevalence and Affecting Factors of Sleep and Circadian Rhythm Disorders in ICU

April 3, 2024 updated by: Shanghai Zhongshan Hospital

Prevalence and Affecting Factors of Sleep and Circadian Rhythm Disorders in ICU: An Observational Study

Most ICU patients experience sleep and circadian disruption (SCD), which causes a profound negative impact on patients, such as prolonged mechanical ventilation, glucose intolerance, and the occurrence of delirium. In order to better promote the alignment of circadian rhythm in ICU patients, this project will explore the prevalence of SCD and a series of influencing factors contributing to SCD in ICU patients, to help construct targeted intervention programs in the future.

Study Overview

Detailed Description

The circadian rhythm refers to the oscillation phenomenon of physiological, biochemical, and behavioral life phenomena of organisms with a 24-hour cycle. The circadian rhythm affects multiple physiological indicators, such as the sleep-wake cycle, hormone levels, heart rate, blood pressure, and metabolic functions. Maintaining a normal circadian rhythm is crucial for human health. However, a series of stressful stressors in the ICU, such as lack of normal light-dark cycle changes, high levels of noise, make sleep and circadian rhythm disruption(SCD) common and severe, and such disruption will have serious negative impacts on patients' clinical outcomes. Therefore, there is an urgent need for effective interventions to assist ICU patients in promoting their sleep and circadian rhythms. The first step in intervention is to understand the current incidence and characteristics of ICU SCD, as well as the factors contributing to such disruption.

To date, there has been limited progress on the current status of SCD prevalence in ICUs. On one hand, there may be significant variability in ICU SCD between individual patients and subgroups, On the other hand, this variability may change over time as patients recover from acute illnesses. This heterogeneity from population and time impedes the development of interventions for SCD. Therefore, there is an urgent need to understand the characteristics, trends of SCD in different patients and the factors influencing these changes.

The overall objective of this project is to explore the status and influencing factors of ICU patients' sleep and circadian rhythms in the first 3 days by conducting a longitudinal study using multiple objective subjective indicators, aiming to more accurately and objectively evaluate the changes in patients' circadian rhythms.

Study Type

Observational

Enrollment (Estimated)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Shanghai, China, 20032
        • Recruiting
        • 180 Fenglin Road
        • Contact:
        • Principal Investigator:
          • Yuxia Zhang, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

In the Surgical Intensive Care Unit (SICU) at Zhongshan Hospital, Fudan University, critically ill adult patients from both surgical and medical specialties are admitted in SICU.

Description

Inclusion Criteria:

  1. Adult patients older than 18 years old.
  2. Patients transferred to ICU during the time period of 8:00-22:00.
  3. Stay in the ICU for more than 12 hours and at least one overnight period.
  4. Patients or their family members are informed and consent to participate in the research.

Exclusion Criteria:

  1. Acute brain injuries within 30 days, such as acute intracranial bleeding, traumatic brain injury, central nervous system infection, or chronic brain injuries lasting over 30 days with an inability to live independently.
  2. Previously diagnosed with mild cognitive impairment or Alzheimer's disease.
  3. Patients affected by blindness or optic nerve disorder.
  4. Patients who are pregnant or breastfeeding.
  5. Patient in prone position, hemodialysis, or ECMO therapy during PSG monitoring
  6. Imminently dying or with a hospice status.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rhythmicity of melatonin levels.
Time Frame: Starting from 3:00 on the first day after admission to the ICU, four blood samples are taken every day (at 3:00, 9:00, 15:00, and 21:00), continuing for three days.
Measuring the patient's circadian rhythm using their melatonin secretion levels.
Starting from 3:00 on the first day after admission to the ICU, four blood samples are taken every day (at 3:00, 9:00, 15:00, and 21:00), continuing for three days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overnight sleep duration
Time Frame: During the first three nights after entering the ICU.
Minutes of sleep from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Wake after sleep onset(WASO)
Time Frame: During the first three nights after entering the ICU.
Minutes of WASO from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Overnight Rapid Eye Movement (REM) proportion
Time Frame: During the first three nights after entering the ICU.
Proportion of Stage REM sleep from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Overnight non-rapid eye movement stage 1 (NREM1) proportion
Time Frame: During the first three nights after entering the ICU.
Proportion of Stage NREM1 sleep from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Overnight non-rapid eye movement stage 2 (NREM2) proportion
Time Frame: During the first three nights after entering the ICU.
Proportion of Stage NREM2 sleep from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Overnight non-rapid eye movement stage 3 (NREM3) proportion
Time Frame: During the first three nights after entering the ICU.
Proportion of Stage NREM3 sleep from 22:00 to 6:00 as measured by portable polysomnography device (Alice PDX)
During the first three nights after entering the ICU.
Sleep period time ratio (sleep continuity)
Time Frame: During the first three nights after entering the ICU.
Nighttime sleep duration divided by the number of nighttime sleep cycles, sleep data is measured by portable polysomnography device (Alice PDX) from 22:00 to 6:00.
During the first three nights after entering the ICU.
Subject sleep quality
Time Frame: Within 12 hours after each PSG measurement
Using the Richards-Campbell Sleep Questionnaire to measure the sleep quality of patients.
Within 12 hours after each PSG measurement
Activity counts
Time Frame: Starting from 22:00 on the first day after admission to the ICU, continuing for three days.
The activity count is recorded by actigraphy.
Starting from 22:00 on the first day after admission to the ICU, continuing for three days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: YuXia Zhang, PhD, Fudan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2024

Primary Completion (Estimated)

January 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

March 14, 2024

First Submitted That Met QC Criteria

April 3, 2024

First Posted (Actual)

April 4, 2024

Study Record Updates

Last Update Posted (Actual)

April 4, 2024

Last Update Submitted That Met QC Criteria

April 3, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

3
Subscribe